Conclusions
In MONALEESA-3, with a follow-up of nearly 6 years, ribociclib + fulvestrant demonstrated the longest mOS observed to date for a first-line population in a phase III clinical trial. This is the third phase III study of ribociclib demonstrating a significant OS advantage in first-line treatment of patients with HR+/HER2− ABC. This analysis adds to the robust body of evidence on the efficacy of ribociclib use across the MONALEESA program and confirms its long-term, consistent OS benefit in treating patients with HR+/HER2− ABC irrespective of ET partner or menopausal status.